Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VISION: tepotinib in advanced non-small cell lung cancer with MET exon 14 skipping alterations or MET amplification
NL-OMON54801Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tepotinib in non-small cell lung cancer (NSCLC), sponsored by Merck & Co.. Started Apr 2019; status: recruiting.
02
Drugs
tepotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON54801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54801.